1-3 of 3
Aditi Mehta
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Utilizing TCR-Seq to Detect Tabelecleucel, an Allogeneic Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy, Post-Infusion

Fiona Ruiz, Tassja J. Spindler, Sumer Arthurs, Tiffany Jehng, Kate Widmann, Joseph M. Benoun, Yuanbin Ru, Aditi Mehta, Rajani Dinavahi, Jason A. Dubovsky, Cokey Nguyen
Journal: Blood
Blood (2022) 140 (Supplement 1): 4966–4967.
https://doi.org/10.1182/blood-2022-157709
Published: 2022
Journal Articles

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV + PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Wei Ye, Susan Prockop
Journal: Blood
Blood (2022) 140 (Supplement 1): 10374–10376.
https://doi.org/10.1182/blood-2022-157766
Published: 2022
Journal Articles

Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant

Susan Prockop, Laurence Gamelin, Rajani Dinavahi, Yan Sun, Weizhi Zhao, Faith Galderisi, Aditi Mehta
Journal: Blood
Blood (2021) 138 (Supplement 1): 887.
https://doi.org/10.1182/blood-2021-147226
Published: 2021